

**Service of Clinical Pharmacology - Laboratory PCL8 - CHUV- Lausanne**Laboratory: 021 314 42 71 (Email: labo.pharmaco-clin@chuv.ch, website: www.chuv.ch/pcl)**DRUG PLASMA LEVEL QUANTIFICATION BY LC-MS/MS | CATALOGUE 2022**Prof. Laurent Decosterd, Dr Eva Choong, Emails: LaurentArthur.Decosterd@chuv.ch or Eva.Choong@chuv.chIn case of **TDM clinical interpretation**: supplement 3.60 CHF / min (Tarmed 00.0141)Dr Pascal André, Email: Pascal.Andre@chuv.ch, Tel: 021 314 25 00 or 021 314 14 04

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
ANTIRETROVIRALS (LA 1084, pts 144) - Analyses twice a week					
Abacavir	Ziagen, in Triumeq	B	Fostemsavir/Temsavir	Rukobia	D
Atazanavir	Reyataz	B	Lamivudine	Trizivir, in Triumeq	B
Bictegravir	Biktarvy	B	Lopinavir	Kaletra	C
Cabotegravir	Vocabria	C	Maraviroc	Celsentri	B
Darunavir	Prezista	B	Nevirapine	Viramune	B
Dolutegravir	Tivicay, in Triumeq	B	Raltegravir	Isentress	B
Doravirine	Pifeltro, in Delstrigo	C	Rilpivirine	Edurant, Rekambys	C
Efavirenz	Stocrin	A	Ritonavir	Norvir ⁽²⁾	B
Elvitegravir	Stribild	B	Tenofovir	Viread, in Descovy, in Eviplera	B
Emtricitabine	Emtriva, in Descovy	C	Zidovudine	Retrovir, in Combivir	D
Etravirine	Intelence	B			

ANTIVIRALS (LA 1084, pts 144) - Analyses twice a week					
Acyclovir	Zovirax	B	Sofosbuvir (+ GS-331007) ⁽³⁾	Sovaldi	D
Ganciclovir	Cymevene	B	Valaciclovir	Valtrex	B
Letermovir	Prevymis	C	Valganciclovir	Valcyte	B
Ribavirin ⁽³⁾	Copegus, Rebetol	B			

ANTIEPILEPTICS (LA 1069, pts 126) - Analyses every working day					
Brivaracetam	Briviact	C	Levetiracetam	Keppra	B
Carbamazepine (+ CBZ-epoxide)	Tegretol	B	Oxcarbazepine (OH-Oxcarbazepine)	Trileptal	B
<i>Clobazam</i>	<i>Urbanyl</i>	C	Perampanel	Fycompa	C
<i>Clonazepam</i>	<i>Rivotril</i>	C	Pregabalin	Lyrica	C
<i>Ethosuximide</i>	<i>Petinimid</i>	C	Rufinamide	Inovelon	C
Eslicarbazepine	Zebinix	C	Topiramate	Topamax	C
Gabapentin	Neurotin	C	Sulthiame	Ospolot	C
Lacosamide	Vimpat	B	Zonisamide	Zonegran	C
Lamotrigine	Lamictal	C			

TARGETED ANTICANCER DRUGS (LA 1772, pts 126) - Analyses once a week					
Abemaciclib	Verzenio	C	Olaparib	Lynparza	C
Alpelisib	Piqray	C	Osimertinib	Tagrisso	C
Asciminib	Scemblix	C	Palbociclib	Ibrance	D
Axitinib	Inlyta	C	Pazopanib	Votrient	D
Bosutinib	Bosulif	C	Ponatinib	Iclusig	C
Cobimetinib	Cotellic	D	Regorafenib (+ M2,M5)	Stivarga	D
Dabrafenib	Tafinlar	D	Ruxolitinib	Jakavi	D
Dasatinib	Sprycel	C	Sorafenib	Nexavar	C
Erlotinib	Tarceva	C	Sunitinib	Sutent	D
Gefitinib	Iressa	D	Tamoxifen / Endoxifen	Tamoxifen	B
Ibrutinib	Imbruvica	C	Trametinib	Mekinist	D
Imatinib	Glivec	A	Vemurafenib	Zelboraf	D
Nilotinib	Tasigna	C			

IMMUNOSUPPRESSIVE AGENTS (LA 1469 pts 135) AND CYTOSTATICS (LA 1772, pts 126) - Analyses once a week					
6-Mercaptopurine (6-TGN, 6-MMP)	Puri-Nethol, Xaluprine	C	<i>Abrocitinib</i>	<i>Cibinqo</i>	C
6-Thioguanine (6-TGN)	Lanvis	C	<i>Baricitinib</i>	<i>Olumiant</i>	C
Azathioprine (6-TGN, 6-MMP)	Imurek	C	<i>Fedratinib</i>	<i>Inrebic</i>	C
<i>Thiopurine S-methyltransferase (TPMT) activity</i>			<i>Tofacitinib</i>	<i>Xeljanz</i>	C
Mycophenolic acid (+ MPAG, AcMPAG)	CellCept, Myfortic	C	<i>Upadacitinib</i>	<i>Rinvoq</i>	C

MATERIAL FOR ALL ANALYSES : 4.9ml K-EDTA tubeAll pre-analytical information on : www.chuv.ch/analyses

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
ANTIBIOTICS (LA 1061, pts 166.5) - Analyses every working day					
Amoxicillin	Clamoxyl	B	Doxycycline	Vibramycin	C
Azithromycin	Zithromax	C	Ertapenem	Invanz	B
Cefazolin	Kefzol	C	Erythromycin	Erythrocin	C
Cefepime	Maxipime	A	Flucloxacillin	Floxapen	B
Cefiderocol	Fetcroja	D	Hydroxychloroquine	Plaquenil	C
Ceftaroline	Zinforo	D	Imipenem (+ Cilastatin)	Tienam	B
Ceftazidime	Fortam	B	Levofloxacin	Tavanic	C
Ceftobiprole	Zevtera	D	Linezolid	Zyvoxid	C
Ceftolozane (+ Tazobactam)	Zerbaxa	D	Meropenem	Meronem	B
Ceftriaxone	Rocephine	B	Metronidazole	Flagyl	C
Cefuroxime	Zinat	C	Moxifloxacin	Avalox	C
Ciprofloxacin	Ciproxine	C	Penicillin G (= benzylpenicillin)	«Grünenthal»	C
Clarithromycin	Klacid	C	Piperacillin (+ Tazobactam)	Tazobac	B
Clindamycin	Dalacin	C	Rifampicin	Rimactan	C
Colistin (+ Colistin methanesulfonate)	Colimycine	B	Tigecyclin	Tygacil	C
Daptomycin	Cubicin	B	Trimethoprim-Sulfamethoxazole	Bactrim	D

ANTIFUNGAL DRUGS (LA 1077, pts 144) - Analyses twice a week					
Anidulafungin	Eraxis	B	Itraconazole / Hydroxy-Itraconazole	Sporanox	B
Caspofungin	Cancidas	B	Posaconazole	Noxafil	B
Fluconazole	Diflucan	B	Voriconazole (+ Voriconazole-NO)	Vfend	A
Isavuconazole	Cresemba	C			

ANTITUBERCULOSIS DRUGS (LA 1061, pts 166.5) - Analyses once a week					
Bedaquiline	Sirturo (EMA)	C	p-Aminosalicic acid (PAS)	Granupas (EMA)	C
Cycloserine	Seromycin (FDA)	C	Pretomanid	Dovprela (EMA)	C
Clofazimine	Lamprene	C	Prothionamide		C
Delamanid (+ metabolite DM6705)	Delytba (EMA)	C	Pyrazinamide	in Rimstar	B
Ethambutol	Myambutol, in Rimstar	B	Rifabutin	Mycobutin	C
Isoniazid (+ acetyl-isoniazid)	Rimactazid, in Rimstar	B	Rifampicin	Rimactan, in Rimstar	B
Levofloxacin: see Antibiotics		C	Rifapentine	Priftin (FDA)	C
Linezolid: see Antibiotics		C	Streptomycin		C
Moxifloxacin: see Antibiotics		C	Sutezolid		C

ANTIPARASITIC (ANTIMALARIAL) DRUGS⁽⁴⁾ - Analyses on demand					
Amodiaquine/Desethyl-amodiaquine		C	Piperaquine	in Eurartesim (EMA)	C
Artemether/Dihydroartemisinin (DHA)	in Riamet	C	Pyrimethamine	Daraprim	C
Artesunate/DHA	Artes.Amivas (EMA)	C	Pyronaridine		C
Chloroquine	Nivaquine	C	Quinine	Qualaquin (FDA)	C
Lumefantrine/Desbutyl-lumefantrine	in Riamet	C	Sulfadoxine		C
Mefloquine	Lariam	C	Hydroxychloroquine: see Antibiotics		C

OTHERS					
Amiodarone	Cordarone	D	Ivacaftor (+M1)	in Orkambi, Trikafta ⁽⁴⁾	D
Levosimendan	Simdax	D	Lumacaftor	in Orkambi ⁽⁴⁾	D
Elexacaftor (+M23)	in Trikafta ⁽⁴⁾	D	Tezacaftor (+M1)	in Trikafta ⁽⁴⁾	D

MATERIAL FOR ALL ANALYSES : 4.9ml K-EDTA tube

All pre-analytical information on: www.chuv.ch/analyses

In gray italic: in development, please contact the laboratory for further details.

In parentheses, the quantification of the mentioned metabolite(s) or the pharmacokinetic booster is provided (at no cost).

(1) Availability of clinical interpretation (by decreasing relevance):

A. TDM is highly recommended and reference intervals are well defined. **B.** TDM can be performed and reference intervals are available. **C.** There is no clear target interval and TDM interpretation is limited to pharmacokinetic plausibility. **D.** There are neither target intervals nor reliable population pharmacokinetic data. No interpretation can be done.

(2) Results provided at no cost if used as a PI-booster. Courtesy of the laboratory.

(3) Development of the quantification of new generation anti-HCV drugs (Elbasvir, Glecaprevir, Grazoprevir, Ledipasvir, Pibrentasvir, Voxilaprevir): on demand

(4) The patient should be informed that the analyse is not within LA list and generally not covered by health insurance, see link below

[OFSP Analysenlist](#)